Is There a Future for AKT Inhibitors in the Treatment of Cancer?

An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER(+)/HER2(-) breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2016-06, Vol.22 (11), p.2599-2601
Main Authors: Jansen, Valerie M, Mayer, Ingrid A, Arteaga, Carlos L
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER(+)/HER2(-) breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway. Clin Cancer Res; 22(11); 2599-601. ©2016 AACRSee related article by Ma et al., p. 2650.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-16-0100